Matches in DBpedia 2016-04 for { ?s ?p "JX-594 is an oncolytic virus (also known as Pexa-Vec) developed by Jennerex and partners: Transgene S.A.; Lee's Pharmaceutical Holdings Ltd.; and Green Cross Corp. Pexa-Vec is designed to target and destroy cancer cells.JX-594 is a vaccinia poxvirus engineered by addition of the GM-CSF gene and deletion of the thymidine kinase gene which limits viral replication to cells with high levels of thymidine kinase, typically seen in cancer cells with a mutated RAS or p53 gene. The virus kills them by lysis and also expresses GM-CSF which may help initiate an anti-tumour immune response.It has orphan drug designation from US FDA and EUMA for the treatment of hepatocellular carcinoma (HCC)."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- JX-594 abstract "JX-594 is an oncolytic virus (also known as Pexa-Vec) developed by Jennerex and partners: Transgene S.A.; Lee's Pharmaceutical Holdings Ltd.; and Green Cross Corp. Pexa-Vec is designed to target and destroy cancer cells.JX-594 is a vaccinia poxvirus engineered by addition of the GM-CSF gene and deletion of the thymidine kinase gene which limits viral replication to cells with high levels of thymidine kinase, typically seen in cancer cells with a mutated RAS or p53 gene. The virus kills them by lysis and also expresses GM-CSF which may help initiate an anti-tumour immune response.It has orphan drug designation from US FDA and EUMA for the treatment of hepatocellular carcinoma (HCC).".
- Q3816624 abstract "JX-594 is an oncolytic virus (also known as Pexa-Vec) developed by Jennerex and partners: Transgene S.A.; Lee's Pharmaceutical Holdings Ltd.; and Green Cross Corp. Pexa-Vec is designed to target and destroy cancer cells.JX-594 is a vaccinia poxvirus engineered by addition of the GM-CSF gene and deletion of the thymidine kinase gene which limits viral replication to cells with high levels of thymidine kinase, typically seen in cancer cells with a mutated RAS or p53 gene. The virus kills them by lysis and also expresses GM-CSF which may help initiate an anti-tumour immune response.It has orphan drug designation from US FDA and EUMA for the treatment of hepatocellular carcinoma (HCC).".